Syntekabio launches new drug development platform STB Cloud in US

Syntekabio,Inc., a South Korean artificial intelligence (AI) drug development company, said on Monday it has launched its cloud-based AI drug development platform STB Cloud in the US market.

STB Cloud is the first cloud-based AI drug development service. Syntekabio's AI new-drug development platform provides solutions without separate hardware or cloud-based software.

With the process of discovering new drug candidates standardized, simplified and automated, the company says the one-click discovery service can be used anytime and anywhere.

The company plans to target both the US and global markets with the goal of transforming the new-drug development process paradigm through STB Cloud.

Syntekabio's first service in the US market through the cloud service is the AI new-drug platform DeepMatcher, which introduces DeepMatcher-Hit. The latter service discovers candidate substances for new synthetic drugs.

The company plans to further expand its range of services to include lead optimization by installing its proprietary platform. 

"We will launch the service in the US market by adding the advanced DeepMatcher into the independently built cloud while working together with domestic pharmaceutical firms and organizations," said Syntekabio CEO Jung Jong-sun.

"In the US market, we plan to establish partnerships in areas such as AI drug development and drug re-creation, to become a global AI drug development platform company," he added.

Write to Jae-Young Han at jyhan@hankyung.com